antibodi thought ahead abt earn
abbott announc launch lab-bas serolog test detect igg antibodi remind serolog
test igg tell hether someon previous infect ith test ill initi avail architect
instrument instrument us laboratori abbott note instrument run
test per hour abbott expect ship close million test eek custom expect ship million test
total april compani ramp million test us june beyond run new alin system abbott
also plan expand test detect antibodi igm near futur understand assay price
abbott plan file eua submiss ith fda abbott ship ithout eua plan ce mark ivd direct
remind abbott alreadi molecular diagnost test system ell point-of-car test id
abbott releas earn tomorrow ill host confer call et link ebcast
expect compani provid updat test continu rate share overweight
thought outlook year
 hile expect test revenu increment posit compani expect abbott still see headw ind
form reduc core diagnost revenu low er lab test associ ith overal physician offic visit
reduc hospit censu due elect procedur postpon also expect medic devic revenu significantli
reduc near-term due elect procedur postpon could stock seen nutrit busi
 ould expect nutrit establish pharmaceut less effect overal
 updat forecast across coverag univers deep dive examin near potenti long-term rippl
expect expect sale billion flat y/i ex-fx vs guidanc around organ
street/bloomberg billion expect ep ell guidanc due bloomberg
expect project sale billion dow report basi flat constant currency/organ
basi abbott initi guidanc organ grow th hich expect compani revis sinc chang
everyth view view broad-strok impact half abbott portfolionam devic
diagnost side ith nutrit epd less impact bloomberg consensu estim billion ep
estim versu bloomberg abbott initi guidanc ep estim versu
consensu
info serolog test
alway stay safe stay healthi well kind feel free reach
serolog test
serolog test measur hether antibodi present amount antibodi person blood antibodi may
initi present earli thu serolog test use diagnos may help tool determin ho
infect past develop immun
igm first antibodi made bodi found mainli blood lymph fluid typic produc rapidli
infect igm typic temporari disappear usual eek product igg abundantli found
antibodi bodi found lymph blood intestin last longer period
know dont know antibodi
studi includ confirm probabl case china median durat igm detect day
interquartil rang hile igg detect median day interquartil rang symptom onset
guo li ph et al profil earli humor respons diagnos novel coronaviru diseas clinic infecti diseas
april pre-print peer-review ed publish medrxiv titl neutral antibodi respons
recov patient cohort implic fan et al neutral antibodi respons covid-
recov patient cohort implic medrxiv neutral antibodi nab import clear viru
import part immun respons protect treatment viral diseas studi plasma
collect recov patient ith mild symptom none patient ere admit icu median
length hospit stay day median diseas durat day investig found recov
patient gener low titer specif nab patient studi titer ere low
detect level medium-low level medium-high high level nab investig found
 ere variat titer nab depend age group ith elderli patient like induc higher level
new viru long-term data determin long immun last data sar outbreak show ed titer
igg neutral antibodi peak month infect ith subsequ declin least year infect
regard reinfect potenti accord updat publish jama april hile evid reinfect evolv
current data experi previou virus ithout substanti season mutat support hypothesi patient
becom reinfect ith viru least mani month year initi infect sb malani del rio
pandem us clinic updat jama publish on-line april
march fda issu updat polici diagnost test ithin updat polici allow ed develop
certain serolog test market use test determin test ere accur reliabl ithout prior fda review
fda note serolog test less complex molecular test use sole identifi antibodi viru
provid adequ disclosur inform provid note thing test review ed fda neg
result rule infect follow -up test ith molecular test consid etc fda
intend object develop distribut test
april fda grant first still eua serolog test intend use clinic lab cellex hich ork
 ith mayo clinic
april fda note ere test develop ho notifi agenc serolog test avail
bio-rad us cover
aytu bioscienc aytu cover
partnership
biomedom privat
dia sorin dia im cover
biomerica bmra us cover
click titl access note
believ great read deep dive examin near potenti long-term rippl effect
think investor visual novel coronaviru giant boulder throw lake creat big initi
splash upon entri rippl ill seen felt reach far shore time initi focu
investor commun big splash creat near-term effect import question difficult
answ er hat effect rippl hat long-term impact healthcar industri
 holeprovid physician patient insur cours med-tech compani report aim
 healthcar physician survey reduc offic visit procedur across multipl specialti
barclay global healthcar survey physician state across differ sub-specialti includ
gastroenterolog endocrinolog dermatolog neurolog hemo-oncolog rheumatolog evalu impact
practic trend particularli offic volum elect procedur prescript pattern nearli physician report
signific declin patient offic visit averag visit around primari reason behind
declin appear patient cancel visit telehealth appoint significantli perhap enough off-set
declin in-person visit major physician indic facil hospit asc offices/surgi-
center implement polici cancel elect procedur led signific reduct surgeri report
list common elect procedur specialti cancel usual suspect like knee hip replac
arthroscopi radiofrequ ablat nerv block spinal fusion stent etc ere list think list greater
might think includ procedur like valv replac tavr laa prevent icd pacemak
cabg peripher intervent endoscopi prostatectomi db also talk implic
 medic suppli devic put take isrg-get readi arn flag
reportw review med-tech takeaw ay barclay global healthcar confer discuss american
colleg surgeon surgeon gener recommend cancel elect procedur review state health system
hospit taken action limit elect procedur action relev medic devic includ
commentari regard build new bed review hat elect procedur discuss product mix
compani review hat product could use effort compani manufactur product
feedback kol call march barclay equiti research global healthcar team host expert
confer call ith senior epidemiologist dr arnold monto md note summar takeaw ay call
hill-rom hold inc upgrad overw eight readi abl assist ith estim least
hillrom sale rental bed legaci elch allyn product thermometri patient monitor blood
pressur physic examin product could use help triag assess monitor aid treatment
patient hillrom also recent acquir hich non-invas ventil anoth hillrom
busi acut care frame hich includ icu bed mani hospit state cite shortag
kstew updat aim doubl capac global demand reiter ow reiter
overw eight rate hillrom market close hillrom announc global demand sever critic product
grow substanti ork significantli ramp product ith goal doubl capac
follow ing area respiratori health icu med-surg smart bed patient monitor diagnost
kstew updat isgr prelim vent contract updat cover announc
preliminari result similar mani med-tech compani ithdrew guidanc cite believ
provid read-through coverag univers also ant provid addit ventil updat
 ell updat put depart human servic
kstew updat trump invok dpa vent ork sign contract ith /mdt other
 hite hous updat on-going trump note invok defens product act ventil
 ork ith sever manufactur includ hillrom view new posit compani
reiter overw eight rate
kstew updat sunday rundow fda issu guidanc doc ventil focu vent edit
give run-dow eekend new provid run-dow ventil provid review fda guidanc
document issu eekend list major manufactur ventil suppli
kstew updat count eather cdc outlin return ork guidelin present
nation academi scienc engin medicin committe find relat temperatur
humid potenti season
kstew updat ny apex vent updat abt dx airtim presid trump other
updat discuss updat ny state trend updat hite hous press brief
ventil ell abbott test
kristen stew art cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
valuat methodolog set price target primarili reli forw ard price-to-earnings methodolog believ stock
maintain premium multipl given top line bottom line grow th prospect pt appli multipl ep
risk may imped achiev barclay research valuat price abbott signific
exposur emerg market intern broadli thu chang fx rate could pressur sale ep result new
product central posit view approv adopt new product therefor anoth risk risk includ
healthcar reform effort medicar reimburs chang product recal fda arn letter
govern regulatori action libr signific driver grow th chang trajectori key risk factor
rate price target histori
prior intra-day chang may publish rate secur overw eight
adjust price target
histor stock price price target may adjust stock split dividend
co usd equal eight/neutr a/cd/ce/d/e/j/k/l/m/n
valuat methodolog set price target primarili reli forw ard price-to-earnings methodolog price target
appli multipl calendar ep
risk may imped achiev barclay research valuat price upsid risk factor
extent becton success integr bard see greater expect revenue/cost synergi shorter time period
resolv alari pump issu greater success ith new product nside fx stronger us dollar commod cost
could greater headw ind risk factor includ time success new product delay resolv alari pump
issu increas competit key product drug-coat balloon infus pump signific chang reimburs
fda govern action
rate price target histori
co
prior intra-day chang may publish rate secur equal eight
adjust price target
histor stock price price target may adjust stock split dividend
valuat methodolog set price target primarili reli forw ard price-to-earnings methodolog price target
appli price-to-earnings multipl calendar year ep
risk may imped achiev barclay research valuat price upsid new product drive
acceler sale ep grow th accret acquisit continu favor hospit capital-expenditure environ
nside less favor trend hospit capital-expenditure delay due slow er uptak new product strengthen us
dollar higher tax rate risk includ signific reimburs chang fda product approv time competit
pressur fda govern action
rate price target histori
prior intra-day chang may publish rate secur overw eight
adjust price target
histor stock price price target may adjust stock split dividend
valuat methodolog set price target primarili reli forw ard price-to-earnings methodolog price target
appli target pe calendar ep estim grow th profil improv expect pe
expand closer peer
risk may imped achiev barclay research valuat price nside risk includ fx rate
strengthen us dollar hich could pressur earn stock perform new product key futur success
compani thu extent compani unabl receiv fda approv could advers impact futur
outlook product includ compani surgic robot platform minim futur iter continu blood glucos
monitor devic transcathet valv system upsid greater success ith new product margin expans risk
includ signific reimburs chang competit pressur product failur fda govern action
rate price target histori
prior intra-day chang may publish rate secur overw eight
adjust price target
histor stock price price target may adjust stock split dividend
unless otherw ise indic price sourc bloomberg reflect close price relev trade market hich
may last avail price time public
